Discover Ono Pharmaceutical's groundbreaking patent for autophagy-inhibiting compounds, targeting various cancers with innovative MEK inhibitors like selumetinib.

近年来随着治疗靶点的发现和新型靶向药物的不断研发，肿瘤治疗已步入精准治疗新时代。近日，2024 年世界肺癌大会（WCLC）和欧洲肿瘤内科学会（ESMO）年会陆续召开，带来肿瘤领域最新前沿进展。会议中，针对 BRAF、MET 14 ...

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

根据在FGFR2 融合+ ICC 细胞中抑制 FGFR后观察到的代谢可塑性，我们接下来探索了针对新出现的代谢弱点提高疗效的可能性。为此，我们测试了联合抑制FGFR和线粒体氧化代谢的效果。ONC212是一种对线粒体蛋白质量控制至关重要的ClpP蛋白酶激动剂，ONC212增强了FGFRi 在ICC13-7 和ICC21 细胞中的疗效，还研究了降低葡萄糖条件对这些反应的影响发，现，ONC212与 ...

Researchers at the University of Massachusetts Amherst and UMass Chan Medical School have demonstrated in mice a new method ...

结直肠癌（CRC）是一种常见的恶性肿瘤，在所有癌症中的发病率（6.1%）位居第三，死亡率（9.4%）居第二位。由于大肠癌的 ...

Discover Ikena Oncology's groundbreaking patent for anti-TREM1 antibodies, designed to boost immune responses and revolutionize cancer treatment.

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and ...

CaMKII activates the HRI/eIF2α signaling pathway and inhibits the proteotoxicity induced by proteasome inhibition through ...